CalciMedica Executes 1-for-5 Reverse Split to Regain Nasdaq Compliance
CALC sits 17% above its 52-week low of $0.461 on light trading volume (0.1× avg).
Summary
CalciMedica filed a Certificate of Amendment to effect a 1-for-5 reverse stock split and reduce authorized shares from 500M to 100M, effective August 28, 2026, to regain Nasdaq compliance.
Key Events · Corporate Governance and Compliance · CALC
-
1-for-5 Reverse Split Executed
Every five shares of common stock will combine into one share effective 5:00 p.m. ET on August 28, 2026, with no change in par value.
-
Authorized Shares Cut 80%
Total authorized common shares reduced from 500,000,000 to 100,000,000, with 10,000,000 preferred shares retained.
-
Nasdaq Compliance Objective
The reverse split is designed to raise the per-share price above Nasdaq's minimum bid requirement, addressing the delisting risk disclosed in prior filings.
-
Split-Adjusted Trading Begins August 31
Shares will trade under ticker CALC on a split-adjusted basis when the market opens August 31, 2026, with new CUSIP 38942Q301.
Analysis · CALC · Life Sciences
CalciMedica has finalized a 1-for-5 reverse stock split effective August 28, 2026, reducing authorized shares from 500 million to 100 million. This is the concrete execution of a plan approved by stockholders on August 19 to address the company's Nasdaq delisting risk. The split will proportionally reduce outstanding shares and adjust all options, warrants, and RSUs, while the authorized share reduction limits future dilution headroom. Trading on a split-adjusted basis begins August 31 under the same ticker CALC.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.